Compare RBCAA & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RBCAA | PGEN |
|---|---|---|
| Founded | 1974 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 1998 | 2013 |
| Metric | RBCAA | PGEN |
|---|---|---|
| Price | $67.35 | $3.43 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 29.9K | ★ 4.7M |
| Earning Date | 05-01-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.62% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $417,495,000.00 | $230,981,000.00 |
| Revenue This Year | $3.93 | $342.78 |
| Revenue Next Year | N/A | $478.46 |
| P/E Ratio | $88.83 | ★ N/A |
| Revenue Growth | ★ 8.50 | N/A |
| 52 Week Low | $56.79 | $1.11 |
| 52 Week High | $78.00 | $5.47 |
| Indicator | RBCAA | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 35.06 | 35.79 |
| Support Level | $64.16 | $2.99 |
| Resistance Level | $72.98 | $5.10 |
| Average True Range (ATR) | 2.20 | 0.28 |
| MACD | -0.38 | -0.10 |
| Stochastic Oscillator | 10.56 | 9.95 |
Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through five reportable segments. It has traditional banking which generates the majority of revenue, Warehouse Lending, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans and receipt and payment of federal.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.